Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study

Canonico Marianne; Olié Valérie; Carcaillon Laure; Tubert-Bitter Pascale; Scarabin Pierre-Yves; the EStrogen and THromboEmbolism Risk (ESTHER) Study Group; on behalf of

doi:10.1160/TH07-09-0536

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 99(01): 246-248
DOI: 10.1160/TH07-09-0536

Letters to the Editor

Schattauer GmbH

Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study

Autoren

Canonico Marianne

¹Inserm, Unité 780, Villejuif, France

²Université Paris-Sud 11, IFR 69, Villejuif, France
Olié Valérie

¹Inserm, Unité 780, Villejuif, France

²Université Paris-Sud 11, IFR 69, Villejuif, France
Carcaillon Laure

¹Inserm, Unité 780, Villejuif, France

²Université Paris-Sud 11, IFR 69, Villejuif, France
Tubert-Bitter Pascale

¹Inserm, Unité 780, Villejuif, France

²Université Paris-Sud 11, IFR 69, Villejuif, France
Scarabin Pierre-Yves

¹Inserm, Unité 780, Villejuif, France

²Université Paris-Sud 11, IFR 69, Villejuif, France

the EStrogen and THromboEmbolism Risk (ESTHER) Study Group

Abstract

Volltext

Referenzen

References
1 Jick H, Slone D, Westerholm B. et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969; 1: 539-542.
2 Wautrecht JC, Galle C, Motte S. et al. The role of ABO blood groups in the incidence of deep vein thrombosis. Thromb Haemost 1998; 79: 688-689.
3 Robert A, Aillaud MF, Eschwege V. et al. ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thromb Haemost 2000; 83: 630-631.
4 Morelli VM, de Visser MC, van Tilburg NH. et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007; 97: 534-541.
5 Tirado I, Mateo J, Soria JM. et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93: 468-474.
6 Mercier B, Oger E, Le Gal G. et al. Phenotypic but not allelic ABO blood group association with risk of venous thrombosis. Thromb Haemost 2005; 93: 388-389.
7 Morelli VM, De Visser MC, Vos HL. et al. ABO blood group genotypes and the risk of venous thrombosis : effect of factor V Leiden. J Thromb Haemost 2005; 3: 183-185.
8 Ohira T, Cushman M, Tsai MY. et al. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2007; 5: 1455-1461.
9 Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
10 Canonico M, Oger E, Plu-Bureau G. et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-845.
11 Straczek C, Oger E, Yon de Jonage-Canonico MB. et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495-500.
12 Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992; 3: 452-6.
13 Ito H, Matsuo K, Saito T. et al. Valid responses to ABO blood type question in self-reporting questionnaire. Asian Pac J Cancer Prev 2001; 2: 315-317.